[en] RIO (Rimonabant In Obesity and related disorders) is a large phase 3 programme (>6600 patients) evaluating the efficacy and safety of rimonabant (5 or 20 mg/day), a CBI receptor antagonist of endocannabinoid system, in obese or overweight patients with or without comorbidities (RIO-Europe and RIO-North America), with untreated dyslipidaemia (RIO-Lipids) or with type 2 diabetes treated with metformin or sulfonylurea (RIO-Diabetes). Compared to placebo, rimonabant 20 mg/day consistently increases weight loss, reduces waist circumference, increases HDL cholesterol, lowers triglyceride levels, diminishes insulin resistance, and reduces the prevalence of metabolic syndrome. Almost half of the metabolic effects, including adiponectin increase, occur beyond weight loss, suggesting a direct peripheral effect of rimonabant.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Van Gaal, L. G.
Despres, J. P.
Pi-Sunyer, X.
Golay, A.
Hanotin, C.
Language :
French
Title :
Le rimonabant ameliore le profit de risque cardio-metabolique chez le sujet obese ou en surpoids: synthese des etudes "RIO".
Alternative titles :
[fr] Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies
Publication date :
2006
Journal title :
Revue Médicale Suisse
ISSN :
1660-9379
Publisher :
Medecine et Hygiène, Switzerland
Special issue title :
Le rimonabant ameliore le profit de risque cardio-metabolique chez le sujet obese ou en surpoids: synthese des etudes "RIO".
Grundy SM. The changing face of cardiovascular risk. J Am Coll Cardiol 2005;46:173-5.
Alberti KGMM, Lefèbvre P (Eds). Type 2 diabetes and the metabolic syndrome in Europe. Eur Heart J 2005;7(Suppl. D):D1-D26.
Després JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001;322:716-20.
Klein S, Burke LE, Bray G A, et al. Clinical implications of obesity with specific focus on cardiovascular disease: A statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-67.
Scheen AJ. Current management strategies for co-existing diabetes mellitus and obesity. Drugs 2003;63:1165-84.
Scheen AJ. Management of the metabolic syndrome. Minerva Endocrinol 2004;29:31-45.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84.
Black SC. Cannabinoid receptor antagonists and obesity. Curr Opin Invest Drugs 2004;5:389-94.
Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005;37:270-5.
Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100.
Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-43.
Makoundou V, Golay A. Nouveau traitement de l'obésité et du syndrome métabolique: le rimonabant. Rev Med Suisse 2006;2:41-5.
Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: A randomized controlled trial. JAMA 2006;295:761-75.
Després JP, Golay A, Sjöström L. Rimonabant in Obesrty-Lipids Study Group. Effects on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, for the RIO-Diabetes Study Group. Effects of rimonabant on body weight, glucose control, and cardiometabolic risk factors in patients with type 2 diabetes. 2006 submitted.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12.
Pi-Sunyer F-X, Després J-P, Scheen A, Van Gaal L. Improvement of metabolic effects with rimonabant beyond the effect attributable to weight loss alone: Pooled one year data from the RIO (Rimonabant In Obesity and Related Metabolic Disorders) program (abstract). JACC 2006;47(Suppl. A),362-A.
Kolotkin RL, Crosby RD, Scheen A, Golay A, Després J-P. Effect of rimonabant on quality of life in overweight/obese patients. Congress of the International Society for Pharmacoeconomics Outcomes and Research (IPSOR), Philadelphia, US, 22 May 2006.
